Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Najat Bouchkouj

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Hematology/Oncology Clinics of North America|June 30, 2022
Regulatory Aspects of Gene Therapy: The Regulatory Life CycleNajat Bouchkouj, Megha Kaushal, Poornima Sharma, et al.
Journal of Health Care for the Poor and Underserved|August 7, 2007
Outreach to immigrant communities: teaching pediatric residents about access to health careRobert J Karp, David Rhee, David Feldman, et al.
The Oncologist|August 19, 2022
FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic LeukemiaNajat Bouchkouj, Xue Lin, Xiaofei Wang, et al.
Journal of the National Cancer Institute|April 30, 2021
Patient-Reported Outcomes in Pediatric Cancer Registration Trials: A US Food and Drug Administration PerspectiveMeena N Murugappan, Bellinda L King-Kallimanis, Gregory H Reaman, et al.
The Oncologist|April 11, 2022
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular LymphomaNajat Bouchkouj, Megan Zimmerman, Yvette L Kasamon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2018
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell LymphomaNajat Bouchkouj, Yvette L Kasamon, R Angelo de Claro, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 3, 2013
A pan-inhibitor of DASH family enzymes induces immune-mediated regression of murine sarcoma and is a potent adjuvant to dendritic cell vaccination and adoptive T-cell therapyBrynn B Duncan, Steven L Highfill, Haiying Qin, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2021
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug AdministrationAndrew Dj Pearson, Claudia Rossig, Crystal Mackall, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Hematology/Oncology Clinics of North America|June 30, 2022
Regulatory Aspects of Gene Therapy: The Regulatory Life CycleNajat Bouchkouj, Megha Kaushal, Poornima Sharma, et al.
Journal of Health Care for the Poor and Underserved|August 7, 2007
Outreach to immigrant communities: teaching pediatric residents about access to health careRobert J Karp, David Rhee, David Feldman, et al.
The Oncologist|August 19, 2022
FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic LeukemiaNajat Bouchkouj, Xue Lin, Xiaofei Wang, et al.
Journal of the National Cancer Institute|April 30, 2021
Patient-Reported Outcomes in Pediatric Cancer Registration Trials: A US Food and Drug Administration PerspectiveMeena N Murugappan, Bellinda L King-Kallimanis, Gregory H Reaman, et al.
The Oncologist|April 11, 2022
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular LymphomaNajat Bouchkouj, Megan Zimmerman, Yvette L Kasamon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2018
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell LymphomaNajat Bouchkouj, Yvette L Kasamon, R Angelo de Claro, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 3, 2013
A pan-inhibitor of DASH family enzymes induces immune-mediated regression of murine sarcoma and is a potent adjuvant to dendritic cell vaccination and adoptive T-cell therapyBrynn B Duncan, Steven L Highfill, Haiying Qin, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2021
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug AdministrationAndrew Dj Pearson, Claudia Rossig, Crystal Mackall, et al.
Pageof 1